Generic Name and Formulations:
Oxytocin 10Units/mL; IV or IM inj.
Indications for PITOCIN:
Initiation or improvement of uterine contractions in vaginal delivery. Adjunct in abortion. Control of postpartum bleeding.
Induction of labor: individualize. Initially 0.5–1milliunit/minute (see literature); adjust by 1–2 milliunits/minute at 30–60 minute intervals. Usual max at term: 9–10 milliunits/minute. Bleeding: IV, see literature. IM: 10Units after delivery of placenta. Abortion: see literature.
In anteparum use: Cephalopelvic disproportion. Unfavorable fetal position. When surgical intervention necessary. Fetal distress if labor is not imminent. Unsatisfactory progress in presence of adequate uterine activity. Hyperactive or hypertonic uterus. Invasive cervical carcinoma, active herpes genitalis, total placenta previa, vasa previa, cord presentation or prolapse or other cases where vaginal delivery is contraindicated or if predisposition for uterine rupture exists.
Use only in presence of qualified personnel. Monitor intrauterine pressure, fetal heart rate, maternal blood pressure.
Avoid use within 4 hours of prophylactic vasoconstriction with caudal block anesthesia. Avoid cyclopropane anesthetics.
Maternal: anaphylaxis, postpartum or subarachnoid hemorrhage, arrhythmias, fatal afibrinogenemia, nausea, vomiting, premature ventricular contraction, pelvic hematoma, water intoxication, hypersensitivity resulting in uterine hypertonicity, spasm, tetany, or rupture. Fetal: bradycardia, arrhythmias, CNS damage, seizure, low Apgar scores, jaundice, retinal hemorrhage, death.
Single-dose vial (1mL)—25
Multi-dose vial (10mL)—1, 25
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Undifferentiated Headaches Common in Children, Adolescents
- Smoking Associated With Increased Relapse Rate in Interferon Beta-Treated Relapsing-Remitting MS
- Frontotemporal Dementia, Frontotemporal Lobar Degeneration Symptoms More Common Later in Life
- No Reduction in Cerebral Perfusion With Intensive Blood Pressure Lowering
- Successful Delirium Prevention in Critically Ill With Dexmedetomidine